aglatimagene besadenovec + valacyclovir

BIOLOGICAL2 trials

Sponsors

Candel Therapeutics, Inc.

Conditions

Prostate CancerProstate Cancer (Adenocarcinoma)Prostate Cancer Patients Treated by Radiotherapy

Phase 2

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

RecruitingNCT07332000

Candel Therapeutics, Inc.Prostate Cancer (Adenocarcinoma), Prostate Cancer Patients Treated by Radiotherapy

Start: 2025-10-30End: 2026-08-01Target: 45Updated: 2026-03-20

Phase 3

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Active, not recruitingNCT01436968

Candel Therapeutics, Inc.Prostate Cancer

Start: 2011-09-30End: 2030-12-31Target: 711Updated: 2025-07-30

Related Papers

Phase 3, randomized, placebo-controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer.

Journal of Clinical Oncology2025-05-281 citations